Q-omics provides the consensus-scored MTCO2P17 profile across patient tissues and cancer cell-line models. MTCO2P17 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTCO2P17 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, MTCO2P17 RNA expression shows 7,520 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where MTCO2P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P17 survival associations across molecular data types. MTCO2P17 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P17 RNA expression–survival associations across cancer types. High MTCO2P17 expression shows unfavorable associations in KIRC, MESO, LIHC and BRCA, but favorable associations in UCS and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MTCO2P17 RNA expression.
This table summarizes MTCO2P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P17 shows lower tumor expression in THCA and KIRC. The THCA box plot shows higher MTCO2P17 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .032).
This table shows molecular features associated with MTCO2P17 in patient tissues and cancer cell lines. In patient samples, MTCO2P17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
